iX Biopharma

Samudera Shipping Line
Price target:
UOB Kay Hian "unrated"

Gainer from favourable freight rates

iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a str

Specialty pharmaceutical company iX Biopharma has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) to collaborate o

ST Engineering
Price target:
RHB “buy” $4.25
CGS-CIMB “buy” $4.00

PhillipCapital is maintaining its “buy” call on Ix Biopharma, but at a lower target price of 44.5 cents.

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer. 

Stock markets have remained volatile as countries take turns going into lockdowns to curb subsequent waves of the Covid-19 virus, creating near-term economic uncertainty.

iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20.

Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents.

iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laborat